Vermillion Inc (VRML) 2.82 $VRML
American Journal of Obstetrics & Gynecology Publishes New Clinical Study on the Relationship Between Imaging and OVA1® in Assessing Risk of Ovarian Cancer
PR Newswire - Thu Mar 20, 8:50AM CDT
(Nasdaq: VRML) -- A new study of OVA1® clinical performance, titled "The Effect of Ovarian Imaging on the Clinical Interpretation of a Multivariate Index Assay," has been released as an online advance publication of The American Journal of Obstetrics & Gynecology.[1] The study examines the relationship between two commonly used imaging methods - ultrasound (US) and computed tomography (CT) - and the OVA1 test result, in assessing the risk of ovarian cancer among patients planning surgery for an ovarian mass. OVA1 is an FDA-cleared blood test that measures the levels of five proteins and then uses a proprietary algorithm and software called OvaCalc® to calculate a single risk score.
Vermillion Reports Fourth Quarter and Full Year 2013 Results
PR Newswire - Thu Mar 06, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, reported on its results for the fourth quarter and full year ended December 31, 2013.
Vermillion to Present at the 26th Annual ROTH Conference on March 11, 2014
PR Newswire - Mon Mar 03, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, has been invited to present at ROTH Capital Partners 26th Annual Conference being held March 10-12, 2014, at the Ritz-Carlton in Dana Point, California.
Vermillion Sets Fourth Quarter and Full Year 2013 Conference Call for Thursday, March 6, 2014
PR Newswire - Wed Feb 26, 3:00PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, March 6, 2014, at 4:30 p.m. Eastern time to discuss results for the fourth quarter and year ended December 31, 2013. Financial results will be issued in a press release prior to the call.
BioAtla Grants BioMotiv Exclusive Worldwide Rights to IL-22 Antibody for Inflammatory Bowel Diseases and Colorectal Cancer
PR Newswire - Wed Feb 19, 7:00AM CST
BioAtla, a global biotechnology company focused on the development of conditionally active biologics (CABs), and BioMotiv, the therapeutics accelerator for The Harrington Project for Discovery & Development, today announced that BioAtla licensed exclusive worldwide rights to BioMotiv to develop and commercialize its TH22 pathway-directed antibody compound for the treatment of inflammatory bowel diseases (IBD) and oncologic indications. In conjunction with the agreement, BioMotiv established Kodosil Bio which will develop all compounds resulting from the license.
Vermillion to Present at Leerink Global Healthcare Conference on February 13
PR Newswire - Fri Jan 31, 7:31AM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, has been invited to present at Leerink Partners' Global Healthcare Conference. The conference will be held at the Waldorf Astoria Hotel in New York City from February 12-13, 2014.
Vermillion Inc reports exercise of USD17.6m warrants in an equity financing transaction
M2 - Fri Dec 20, 5:05AM CST
Multivariate diagnostics company Vermillion Inc (NasdaqCM :VRML) announced on Thursday that its investors have exercised warrants to purchase 12.1m shares of its common stock at an exercise price of USD1.46 per share from an equity financing transaction that closed in May 2013.
Vermillion Completes $17.6 Million Warrant Exercise
PR Newswire - Thu Dec 19, 5:04PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, announced that Oracle Investment Management, Jack W. Schuler, Matthew W. Strobeck and certain other investors have exercised warrants to purchase 12.1 million shares of Vermillion common stock at an exercise price of $1.46 per share.
2013 Report on the International Biomarkers Market - Includes Forecasts to 2018
M2 - Thu Dec 19, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/jjq7jz/biomarkers_market) has announced the addition of the "2013 Report on the International Biomarkers Market - Includes Forecasts to 2018" report to their offering. Biomarkers comprise definite cells, genes, molecules, gene products, enzymes, or hormones which are objectively measured as an indicator of typical biological processes, pathogenic processes, or pharmacologic response to a therapeutic intrusion. Major application areas of biomarkers are early disease diagnosis and prevention, drug target recognition, and drug discovery and development. The global market showcases high growth potential in the near future. This market is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018. The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.) Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Biomarkers Market, By Discovery Technologies 5 Services Market Of Biomarkers 6 Biomarkers Application Market 7 Biomarkers Indication Market 8 Geographical Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories - BGI - Bayer Ag - Bristol-Myers Squibb - Caprion Proteomics Inc - Crescendo Bioscience - Eisai Co Ltd - Epiontis GMBH - Epistem Holdings PLC - Eurogentec SA - Evotec AG - Glaxosmithkline PLC - Ipsen - Johnson & Johnson - Merck & Co - Micromedic Technologies Ltd - Myriad Genetics Inc - Nextgen Sciences Inc - Novartis International AG - Ocimum Biosolutions Ltd - Pacific Biomarkers Inc - Pfizer Inc - Pronota NV - Proteome Sciences Plc - Qiagen Nv - Quintiles Transnational Corporation - Roche Diagnostics Limited - Sanofi-Aventis - Siemens Healthcare - Trans-Hit Biomarkers Inc - Vermillion Inc For more information visit http://www.researchandmarkets.com/research/jj...ers_market
Vermillion Inc names Marian E. Sacco as SVP of Sales
M2 - Wed Dec 18, 5:50AM CST
Diagnostics company Vermillion Inc (NasdaqCM:VRML) revealed on Tuesday that it has elected Marian E. Sacco as senior vice president of its sales and marketing and chief commercial officer.
Vermillion Appoints Marian E. Sacco as SVP of Sales and Marketing and Chief Commercial Officer
PR Newswire - Tue Dec 17, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, has appointed Marian E. Sacco as senior vice president of sales and marketing and chief commercial officer.
Vermillion Reports Results of 2013 Annual Meeting
PR Newswire - Mon Dec 16, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, reported the voting results from its annual meeting of its stockholders held December 12, 2013:
Vermillion Inc's board names James T. LaFrance as chairman
M2 - Mon Dec 16, 6:18AM CST
Diagnostics company Vermillion Inc (NasdaqCM:VRML) reported on Friday the appointment of James T. LaFrance as a member as well as chairman of the board of directors effective 12 December 2013.
Vermillion Board of Directors Elects James T. LaFrance as Chairman
PR Newswire - Fri Dec 13, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, announced James T. LaFrance has been appointed a member of its board and was elected chairman of the board on December 12, 2013. Pursuant to the equity financing transaction announced on May 9, 2013, LaFrance was nominated by Jack W. Schuler, Vermillion's largest private shareholder.
Global Cancer Diagnostic Testing Market Report 2013
M2 - Fri Nov 15, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/fp8dbc/cancer_diagnostic) has announced the addition of the "Global Cancer Diagnostic Testing Market Report 2013" report to their offering. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Abbott Diagnostics - Bard Diagnostics, Inc. - Byk Gulden - Cepheid - DRG International, Inc. - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Geron Corporation - Hologic, Inc. (formerly Cytyc Corporation) - Immunicon Corporation (now Veridex, LLC) - Immunomedics, Inc. - LabCorp - Myriad Genetics, Inc. - Nexell Therapeutics, Inc. - Oncotech, Inc. - Polymedco, Inc. - Princeton BioMeditech Corporation - Qiagen - Roche (F. Hoffman-La Roche, Ltd.) - Sanko Junyaku Co., Ltd. - Siemens Heathcare Diagnostics - Tosoh Corporation (Bioscience division) - Ventana Medical Systems, Inc. - Veridex, LLC - Vermillion, Inc. - Worldwide Medical Corporation - Xenomics, Inc. (TrovaGene, Inc.) For more information visit http://www.researchandmarkets.com/research/fp...diagnostic
Vermillion Reports Third Quarter 2013 Results
PR Newswire - Thu Nov 14, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the third quarter ended September 30, 2013.
Faruqi & Faruqi, LLP Launches an Investigation against Vermillion, Inc. (VRML) for Potential Breaches of Fiduciary Duties by its Board of Directors
Business Wire - Wed Nov 13, 11:05AM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Vermillion, Inc. ("Vermillion" or the "Company"
(NasdaqCM: VRML) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for the Amended and Restated 2010 Stock Incentive Plan.
American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillion's Ovarian Cancer Test, OVA1
PR Newswire - Tue Nov 12, 8:00AM CST
A new clinical study published in The American Journal of Obstetrics & Gynecology has reported superior sensitivity of OVA1® for presurgical triage of ovarian cancer in a large intended-use population, compared with commonly used risk assessment methods.
American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillion's OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
PR Newswire - Tue Nov 12, 7:31AM CST
A new study of OVA1® clinical performance in the presurgical detection of ovarian cancer, entitled "Clinical Performance of a Multivariate Index Assay For Detecting Early-Stage Ovarian Cancer," has been published in The American Journal of Obstetrics & Gynecology.
Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
PR Newswire - Thu Oct 31, 7:31AM CDT
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, November 14, 2013, at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2013. Financial results will be issued in a press release prior to the call.
American Journal of Obstetrics & Gynecology Publishes New Clinical Study on the Relationship Between Imaging and OVA1® in Assessing Risk of Ovarian Cancer
PR Newswire - Thu Mar 20, 8:50AM CDT
(Nasdaq: VRML) -- A new study of OVA1® clinical performance, titled "The Effect of Ovarian Imaging on the Clinical Interpretation of a Multivariate Index Assay," has been released as an online advance publication of The American Journal of Obstetrics & Gynecology.[1] The study examines the relationship between two commonly used imaging methods - ultrasound (US) and computed tomography (CT) - and the OVA1 test result, in assessing the risk of ovarian cancer among patients planning surgery for an ovarian mass. OVA1 is an FDA-cleared blood test that measures the levels of five proteins and then uses a proprietary algorithm and software called OvaCalc® to calculate a single risk score.
Vermillion Reports Fourth Quarter and Full Year 2013 Results
PR Newswire - Thu Mar 06, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, reported on its results for the fourth quarter and full year ended December 31, 2013.
Vermillion to Present at the 26th Annual ROTH Conference on March 11, 2014
PR Newswire - Mon Mar 03, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, has been invited to present at ROTH Capital Partners 26th Annual Conference being held March 10-12, 2014, at the Ritz-Carlton in Dana Point, California.
Vermillion Sets Fourth Quarter and Full Year 2013 Conference Call for Thursday, March 6, 2014
PR Newswire - Wed Feb 26, 3:00PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, March 6, 2014, at 4:30 p.m. Eastern time to discuss results for the fourth quarter and year ended December 31, 2013. Financial results will be issued in a press release prior to the call.
BioAtla Grants BioMotiv Exclusive Worldwide Rights to IL-22 Antibody for Inflammatory Bowel Diseases and Colorectal Cancer
PR Newswire - Wed Feb 19, 7:00AM CST
BioAtla, a global biotechnology company focused on the development of conditionally active biologics (CABs), and BioMotiv, the therapeutics accelerator for The Harrington Project for Discovery & Development, today announced that BioAtla licensed exclusive worldwide rights to BioMotiv to develop and commercialize its TH22 pathway-directed antibody compound for the treatment of inflammatory bowel diseases (IBD) and oncologic indications. In conjunction with the agreement, BioMotiv established Kodosil Bio which will develop all compounds resulting from the license.
Vermillion to Present at Leerink Global Healthcare Conference on February 13
PR Newswire - Fri Jan 31, 7:31AM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, has been invited to present at Leerink Partners' Global Healthcare Conference. The conference will be held at the Waldorf Astoria Hotel in New York City from February 12-13, 2014.
Vermillion Inc reports exercise of USD17.6m warrants in an equity financing transaction
M2 - Fri Dec 20, 5:05AM CST
Multivariate diagnostics company Vermillion Inc (NasdaqCM :VRML) announced on Thursday that its investors have exercised warrants to purchase 12.1m shares of its common stock at an exercise price of USD1.46 per share from an equity financing transaction that closed in May 2013.
Vermillion Completes $17.6 Million Warrant Exercise
PR Newswire - Thu Dec 19, 5:04PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, announced that Oracle Investment Management, Jack W. Schuler, Matthew W. Strobeck and certain other investors have exercised warrants to purchase 12.1 million shares of Vermillion common stock at an exercise price of $1.46 per share.
2013 Report on the International Biomarkers Market - Includes Forecasts to 2018
M2 - Thu Dec 19, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/jjq7jz/biomarkers_market) has announced the addition of the "2013 Report on the International Biomarkers Market - Includes Forecasts to 2018" report to their offering. Biomarkers comprise definite cells, genes, molecules, gene products, enzymes, or hormones which are objectively measured as an indicator of typical biological processes, pathogenic processes, or pharmacologic response to a therapeutic intrusion. Major application areas of biomarkers are early disease diagnosis and prevention, drug target recognition, and drug discovery and development. The global market showcases high growth potential in the near future. This market is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018. The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.) Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Biomarkers Market, By Discovery Technologies 5 Services Market Of Biomarkers 6 Biomarkers Application Market 7 Biomarkers Indication Market 8 Geographical Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories - BGI - Bayer Ag - Bristol-Myers Squibb - Caprion Proteomics Inc - Crescendo Bioscience - Eisai Co Ltd - Epiontis GMBH - Epistem Holdings PLC - Eurogentec SA - Evotec AG - Glaxosmithkline PLC - Ipsen - Johnson & Johnson - Merck & Co - Micromedic Technologies Ltd - Myriad Genetics Inc - Nextgen Sciences Inc - Novartis International AG - Ocimum Biosolutions Ltd - Pacific Biomarkers Inc - Pfizer Inc - Pronota NV - Proteome Sciences Plc - Qiagen Nv - Quintiles Transnational Corporation - Roche Diagnostics Limited - Sanofi-Aventis - Siemens Healthcare - Trans-Hit Biomarkers Inc - Vermillion Inc For more information visit http://www.researchandmarkets.com/research/jj...ers_market
Vermillion Inc names Marian E. Sacco as SVP of Sales
M2 - Wed Dec 18, 5:50AM CST
Diagnostics company Vermillion Inc (NasdaqCM:VRML) revealed on Tuesday that it has elected Marian E. Sacco as senior vice president of its sales and marketing and chief commercial officer.
Vermillion Appoints Marian E. Sacco as SVP of Sales and Marketing and Chief Commercial Officer
PR Newswire - Tue Dec 17, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, has appointed Marian E. Sacco as senior vice president of sales and marketing and chief commercial officer.
Vermillion Reports Results of 2013 Annual Meeting
PR Newswire - Mon Dec 16, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, reported the voting results from its annual meeting of its stockholders held December 12, 2013:
Vermillion Inc's board names James T. LaFrance as chairman
M2 - Mon Dec 16, 6:18AM CST
Diagnostics company Vermillion Inc (NasdaqCM:VRML) reported on Friday the appointment of James T. LaFrance as a member as well as chairman of the board of directors effective 12 December 2013.
Vermillion Board of Directors Elects James T. LaFrance as Chairman
PR Newswire - Fri Dec 13, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, announced James T. LaFrance has been appointed a member of its board and was elected chairman of the board on December 12, 2013. Pursuant to the equity financing transaction announced on May 9, 2013, LaFrance was nominated by Jack W. Schuler, Vermillion's largest private shareholder.
Global Cancer Diagnostic Testing Market Report 2013
M2 - Fri Nov 15, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/fp8dbc/cancer_diagnostic) has announced the addition of the "Global Cancer Diagnostic Testing Market Report 2013" report to their offering. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Abbott Diagnostics - Bard Diagnostics, Inc. - Byk Gulden - Cepheid - DRG International, Inc. - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Geron Corporation - Hologic, Inc. (formerly Cytyc Corporation) - Immunicon Corporation (now Veridex, LLC) - Immunomedics, Inc. - LabCorp - Myriad Genetics, Inc. - Nexell Therapeutics, Inc. - Oncotech, Inc. - Polymedco, Inc. - Princeton BioMeditech Corporation - Qiagen - Roche (F. Hoffman-La Roche, Ltd.) - Sanko Junyaku Co., Ltd. - Siemens Heathcare Diagnostics - Tosoh Corporation (Bioscience division) - Ventana Medical Systems, Inc. - Veridex, LLC - Vermillion, Inc. - Worldwide Medical Corporation - Xenomics, Inc. (TrovaGene, Inc.) For more information visit http://www.researchandmarkets.com/research/fp...diagnostic
Vermillion Reports Third Quarter 2013 Results
PR Newswire - Thu Nov 14, 3:01PM CST
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the third quarter ended September 30, 2013.
Faruqi & Faruqi, LLP Launches an Investigation against Vermillion, Inc. (VRML) for Potential Breaches of Fiduciary Duties by its Board of Directors
Business Wire - Wed Nov 13, 11:05AM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Vermillion, Inc. ("Vermillion" or the "Company"
(NasdaqCM: VRML) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for the Amended and Restated 2010 Stock Incentive Plan. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillion's Ovarian Cancer Test, OVA1
PR Newswire - Tue Nov 12, 8:00AM CST
A new clinical study published in The American Journal of Obstetrics & Gynecology has reported superior sensitivity of OVA1® for presurgical triage of ovarian cancer in a large intended-use population, compared with commonly used risk assessment methods.
American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillion's OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
PR Newswire - Tue Nov 12, 7:31AM CST
A new study of OVA1® clinical performance in the presurgical detection of ovarian cancer, entitled "Clinical Performance of a Multivariate Index Assay For Detecting Early-Stage Ovarian Cancer," has been published in The American Journal of Obstetrics & Gynecology.
Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
PR Newswire - Thu Oct 31, 7:31AM CDT
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, November 14, 2013, at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2013. Financial results will be issued in a press release prior to the call.
